BioInsights - Gene delivery platform evolution part 2: non-viral - spotlight

CELL AND GENE THERAPY INSIGHTS

June 2023

Gene delivery platform evolution part 2: non-viral

Download PDF

Foreword

Gene delivery platform evolution part 2: non-viral—Foreword

Gene delivery platform evolution part 2: non-viral—Foreword

Lynn Zechiedrich

Expert Insight

The supporting role of plasmids in gene & cell therapy

The supporting role of plasmids in gene & cell therapy

Duarte Prazeres

Interview

Exploring current shortfalls and potential improvements for non-viral gene delivery in cystic fibrosis

Exploring current shortfalls and potential improvements for non-viral gene delivery in cystic fibrosis

Uta Griesenbach

Exploring the application of doggybone DNA to facilitate non-viral gene therapy delivery to hemophilia patients

Exploring the application of doggybone DNA to facilitate non-viral gene therapy delivery to hemophilia patients

Carol H Miao

Developing non-viral delivery & cell engineering technologies for <em>ex vivo</em> T cell immunotherapies

Developing non-viral delivery & cell engineering technologies for ex vivo T cell immunotherapies

Julie Shi, Nirveek Bhattacharjee

Expanding the potential of <em>in vivo</em> cell therapy with tLNP-RNAs (targeted lipid nanoparticle-RNA)

Expanding the potential of in vivo cell therapy with tLNP-RNAs (targeted lipid nanoparticle-RNA)

Podcast

Non-viral methods for <em>ex vivo</em> cell & gene therapy: is the future non-viral?

Non-viral methods for ex vivo cell & gene therapy: is the future non-viral?

Valeria Annibaldi, Andrea Toell

FastFacts

Reducing risk for cell therapy manufacturing with a battle-tested electroporation platform

Reducing risk for cell therapy manufacturing with a battle-tested electroporation platform

Andrew Mancini

Addressing purification challenges: biological pipeline diversity and smaller manufacturing scales

Addressing purification challenges: biological pipeline diversity and smaller manufacturing scales

Sushma Nayak Teichert

Webinars

Enabling RNA therapeutics: innovative cationic lipids to improve LNP formulation

Enabling RNA therapeutics: innovative cationic lipids to improve LNP formulation

C Gueguen, M Hellal, J Depollier